Assessment of hearing dysfunction in patients with Graves’ disease and thyroid eye disease without or with teprotumumab
Published: 27 August 2024| Version 1 | DOI: 10.17632/tgj5v33xkk.1
Contributor:
Terry SmithDescription
Supplemental Data.
Files
Categories
Adverse Event, Hearing Loss